CiteULike
Facebook
Mendeley
Twitter
This article is- freely available
- re-usable
Cancers 2010, 2(2), 955-969; doi:10.3390/cancers2020955
Review
Systemic Therapy of Non-Resectable Metastatic Melanoma
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany
* Author to whom correspondence should be addressed.
Received: 8 March 2010; in revised form: 11 May 2010 / Accepted: 12 May 2010 / Published: 26 May 2010
(This article belongs to the Special Issue Current Concepts in the Diagnosis and Treatment of Cutaneous Melanoma)
Download PDF Full-Text [123 KB, uploaded 26 May 2010 10:03 CEST]
Abstract: In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy.
Keywords: melanoma; metastatic; chemotherapy; targeted therapy; small molecules
Article Statistics
Click here to load and display the download statistics.Cite This Article
MDPI and ACS Style
Orouji, A.; Goerdt, S.; Utikal, J. Systemic Therapy of Non-Resectable Metastatic Melanoma. Cancers 2010, 2, 955-969.
AMA StyleOrouji A, Goerdt S, Utikal J. Systemic Therapy of Non-Resectable Metastatic Melanoma. Cancers. 2010; 2(2):955-969.
Chicago/Turabian StyleOrouji, Azadeh; Goerdt, Sergij; Utikal, Jochen. 2010. "Systemic Therapy of Non-Resectable Metastatic Melanoma." Cancers 2, no. 2: 955-969.